Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBP NASDAQ:BFRG NASDAQ:LEXX NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.36+2.7%$0.00$0.22▼$15.80$17.17M0.747.58 million shs946,163 shsBFRGBullfrog AI$1.50+0.7%$1.68$1.23▼$4.84$14.03M0.48380,803 shs180,031 shsLEXXLexaria Bioscience$0.87$0.96$0.79▼$4.38$17.02M0.79146,600 shs105,576 shsPLRZPolyrizon$0.97-7.7%$4.66$0.55▼$1,200.00$5.59MN/A6.45 million shs981,207 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma+10.10%+7.36%-0.82%+34,999,900.00%+34,999,900.00%BFRGBullfrog AI+1.36%0.00%-14.37%-10.24%-50.66%LEXXLexaria Bioscience+6.81%-1.79%-13.86%-36.96%-70.71%PLRZPolyrizon+0.96%+47.20%+30.89%-98.82%+104,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASBPAspire BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ABFRGBullfrog AI0.717 of 5 stars0.02.00.00.03.22.50.0LEXXLexaria Bioscience1.9672 of 5 stars3.52.00.00.01.01.70.6PLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/ABFRGBullfrog AI 0.00N/AN/AN/ALEXXLexaria Bioscience 3.00Buy$5.00474.71% UpsidePLRZPolyrizon 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PLRZ, ASBP, LEXX, and BFRG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/ABFRGBullfrog AI$60K235.50N/AN/A$0.57 per share2.63LEXXLexaria Bioscience$615.92K24.80N/AN/A$0.48 per share1.81PLRZPolyrizonN/AN/AN/AN/A$315.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-508.70%N/ABFRGBullfrog AI-$6.99M-$0.81N/A∞N/AN/A-163.23%-139.94%N/ALEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-143.50%-124.99%N/APLRZPolyrizon-$1.54MN/A0.00∞N/AN/AN/AN/AN/ALatest PLRZ, ASBP, LEXX, and BFRG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.220.22BFRGBullfrog AIN/A4.874.87LEXXLexaria BioscienceN/A4.244.24PLRZPolyrizonN/A10.1610.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%BFRGBullfrog AI0.96%LEXXLexaria Bioscience13.06%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%BFRGBullfrog AI33.90%LEXXLexaria Bioscience26.40%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/ABFRGBullfrog AI49.42 million6.22 millionNot OptionableLEXXLexaria Bioscience717.56 million12.92 millionNot OptionablePLRZPolyrizonN/A5.33 millionN/AN/APLRZ, ASBP, LEXX, and BFRG HeadlinesRecent News About These CompaniesPolyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15 at 12:54 AM | finanznachrichten.dePolyrizon retains Nasdaq listing following hearings panelJuly 15 at 12:54 AM | msn.comPolyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15 at 7:55 AM | globenewswire.comPolyrizon’s nasal drug delivery system shows promising resultsJune 14, 2025 | uk.investing.comPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its ...June 12, 2025 | bakersfield.comBPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS TherapeuticsJune 12, 2025 | globenewswire.comPolyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution ConcernsMay 23, 2025 | quiverquant.comQPolyrizon Announces Receipt of Nasdaq Delisting NoticeMay 23, 2025 | globenewswire.comPolyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025May 22, 2025 | tipranks.comPolyrizon Emerges with Positive Preclinical Data on Nasal Protection PlatformMay 21, 2025 | globenewswire.comPolyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant ExercisesMay 14, 2025 | tipranks.comPolyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | finanznachrichten.dePolyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | globenewswire.comPolyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail InterestMay 5, 2025 | msn.comPolyrizon reports safety study results for PL-14 Allergy Blocker formulationApril 26, 2025 | markets.businessinsider.comPolyrizon Ltd.: Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | finanznachrichten.dePolyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | globenewswire.comPolyrizon Ltd. Shareholders Approve Key Amendments at Annual MeetingApril 17, 2025 | tipranks.comPolyrizon Faces Nasdaq Compliance ChallengeApril 11, 2025 | tipranks.comPolyrizon Receives Nasdaq Notification Regarding Minimum Bid RequirementsApril 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRZ, ASBP, LEXX, and BFRG Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.36 +0.01 (+2.68%) As of 04:00 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Bullfrog AI NASDAQ:BFRG$1.50 +0.01 (+0.67%) Closing price 04:00 PM EasternExtended Trading$1.50 +0.00 (+0.33%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Lexaria Bioscience NASDAQ:LEXX$0.87 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$0.89 +0.02 (+2.76%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Polyrizon NASDAQ:PLRZ$0.97 -0.08 (-7.66%) As of 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
